Skip to main content
. 2015 Jun 3;10:3779–3790. doi: 10.2147/IJN.S83279

Figure 5.

Figure 5

NanoATV/r and FA-nanoATV/r biodistribution in kidney, spleen, and liver as quantified by UPLC-MS/MS.

Notes: ATV concentration in tissues is shown for nanoATV/r in (A) LPS and (B) nanoATV/r treated mice. Data are presented as mean ± SEM, *P<0.05 considered significant using Student’s t-test. Panel A and B are days 7 and 14 after nanoformulation treatment, respectively.

Abbreviations: nanoATV/r, nanoformulated ritonavir (RTV)-boosted atazanavir (ATV); FA, folic acid; UPLC-MS/MS, ultraperformance liquid chromatography tandem mass spectrometry; LPS, lipopolysaccharide.